Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1997-10-07
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514420, 514912, A61K 3140
Patent
active
056748884
ABSTRACT:
The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e.g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.
REFERENCES:
patent: 2798053 (1957-07-01), Brown
patent: 3732865 (1973-05-01), Higuchi et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3887699 (1975-06-01), Yolles
patent: 4136250 (1979-01-01), Mueller et al.
patent: 4192827 (1980-03-01), Mueller et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4454151 (1984-06-01), Waterbury
patent: 4522826 (1985-06-01), Sunshine et al.
patent: 4543251 (1985-09-01), Kamishita
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4617299 (1986-10-01), Knepper
patent: 4670254 (1987-06-01), Kamishita
patent: 4690927 (1987-09-01), Voss et al.
patent: 4711782 (1987-12-01), Okada et al.
patent: 4711906 (1987-12-01), von Stetten et al.
patent: 4757060 (1988-07-01), Lukacsko et al.
patent: 4757089 (1988-07-01), Epstein
patent: 4777174 (1988-10-01), Sunshine et al.
patent: 4829088 (1989-05-01), Doulakas
patent: 4855293 (1989-08-01), Collington et al.
patent: 4876250 (1989-10-01), Clark
patent: 4880742 (1989-11-01), Hayaishi et al.
patent: 4904649 (1990-02-01), Schwartz
patent: 4917886 (1990-04-01), Asche et al.
patent: 4948805 (1990-08-01), Ziggiotti et al.
patent: 4960799 (1990-10-01), Nagy
patent: 4971802 (1990-11-01), Tarcsay et al.
patent: 4973469 (1990-11-01), Mulligan et al.
patent: 4980170 (1990-12-01), Schneider et al.
patent: 4999379 (1991-03-01), Fankhauser
patent: 5036097 (1991-07-01), Floyd et al.
patent: 5110493 (1992-05-01), Cherng-Chyi et al.
patent: 5124154 (1992-06-01), Babcock et al.
patent: 5190762 (1993-03-01), Yarosh
patent: 5192535 (1993-03-01), Davis et al.
patent: 5200453 (1993-04-01), Janssen
patent: 5270052 (1993-12-01), Gelfand et al.
patent: 5304561 (1994-04-01), Faezeh
patent: 5314909 (1994-05-01), Dollerup
patent: 5474985 (1995-12-01), Polansky et al.
The Merck Index, Eleventh Edition, 1989. pp. 786 and 787.
Alvarado, J.A. et al.--Human Trabecular Cells, Invest. Ophthalmol. Vis. Sci. 23:464-478 (1982).
Babizhayev, M.A. et al.--Lipid Peroxidation in Open-angle Glaucoma, Invest. Opthalmol. Vis. Sci. 67:371-377 (1989).
Bengtsson, B.--Incidence of Manifest Glaucoma, British J. of Ophthalmology, 73:438-487 (1989).
Bhuyan, K.C. et al.--Regulation of Hydrogen Peroxide in Eye Humors: Effect of 3-Amino-1H-1,2,4-Triazole on Catalase and Glutathione Peroxidase of Rabbit Eye, Biochmica et Biophysica Acta 497:641-651 (1977).
Bhuyan, K.C. et al--Mechanism of Cataractogenesis Induced by 3-amino-1H-1,2,4-triazole. I: Morphology and Histopathology of Cataract and the Role of Catalase in the Regulation of H2O2 in the Eye, Biochemical and Clinical Aspects of Oxygen, 785-796 (1979).
Clark, A.F.--Evaluation of Anti-Glaucoma Compounds And Discovery Of Pathogenic Mechanisms Using Perfusion Cultured Human Eyes, Exp. Eye Res. 55:266 (1992).
Ellis, P.P.--Basic Considerations (Chap. 1), Therapy of Diseases of the Cornea (Chap. 11), Therapy of Glaucomas (Chap 13), Ocular Therapeutics and Pharmacology, pp. 3-27, 137-157, 162-186 (7th ed 1985).
Epstein, D.L.--Chandler and Grant's Glaucoma, pp. 3-5, 129-143, 181-183, 191, 194-195, 201-210, 211, 293-294, 311, 320-321, 352-379, 397 and 403-407 (3d ed. 1986).
Flach, A.J.--Cyclo-oxygenase Inhibitors in Opthalmology, Survey of Ophthalmology, 36:259-284 (1992).
Fauss, D.J. et al.--Glucocorticoid (GC) Effects on HTM Cells: Biochemical Approaches and Growth Factor Responses, Basic Aspects of Glaucoma Research III, pp. 319-330 (1993).
Giblin, F.J. et al.--The Role of Glutathione Metabolism in the Detoxification of H2O2 in Rabbit Lens, Invest. Ophthalmol. Vis. Sci. 22:330-335 (1982).
Huk, B. et al.--Anti-Inflammatory Treatment after Argon Laser Trabeculoplasty, Ophthalmologica 203: 24-29 (1991).
Insel, P.A. et al.--Analgesic-Antipyretics and Antiinflammatory Agents; Drugs Employed in the Treatment of Rheumatoid Arthritis and Gout, Goodman and Gilman's The Pharmacological Basis of Therapeutics, pp. 638-641 (8th ed. 1990).
Kahn, M.G. et al.--Glutathione in Calf Trabecular Meshwork and its Relation to Aqueous Humor Outflow Facility, Invest. Ophthalmol. Vis. Sci. 24:1283-1287 (1983).
Klemetti, A.--The Dexamethason Provocative Test: A Predictive Tool for Glaucoma?, Acta Ophthalmol. 68:29-33 (1990).
Langer, R.--Controlled Release of Macromolecules, Chem. Tech. 12:98-105 (1982).
Lee, V.H.L.--Review: New Directions in the Optimization of Ocular Drug Delivery, J. Ocular Pharmacol. 6:157-164 (1990).
Leske, M.C. et al.--Estimating Incidence from Age-Specific Prevalence in Glaucoma, Amer. J. Epidemiol. 113:606-613 (1981).
Lombardino, J.G.--Nonsteroidal Anti-inflammatory Drugs. Chapter Two: Inflammation--Mechansims and Mediators, pp. 75-109 (1985).
McGraw-Hill Encyclopedia of Science and Technology: Eye (vertebrate) 8:544-552 (6th ed. 1987).
McGraw-Hill Encyclopedia of Science and Technology: Glaucoma 8:131-132 (6th ed. 1987).
Mullins, J.D. et al.--Ophthalmic Preparations, Remington's Pharmaceutical Sciences, Chap. 86, pp. 1581-1595 (18th ed. 1990).
Nguyen, K.P. et al--Hydrogen Peroxide Removal by the Calf Aqueous Outflow Pathway, Invest. Ophthalmol. Vis. Sci. 29:976-981 (1988).
Nguyen, T.D. et al.--Glucocorticoid (GC) Effects on HTM Cells: Molecular Biology Approaches, Basic Aspects of Glaucoma Research III, pp. 330-343 (1993).
Polansky, J.R. et al.--Cellular Mechanisms Influencing the Aqueous Humor Outflow Pathway, Principles and Practice of Ophthalmology, Chap. 13, pp. 226-251 (1994).
Polansky, J.R. et al.--Cellular Injury from Sustained vs. Acute Hydrogen Peroxide Exposure in Cultured Human Corneal Endothelium and Human Lens Epithelium, CLAO Journal Supp. 16:S23-S29 (1990).
Polansky, J.R. et al.--Human Trabecular Cells, Invest. Ophthalmol. Vis. Sci. 18:1043-1049 (1979).
Polansky, J.R. et al.--Studies on Human Trabecular Cells Propagated in Vitro, Vision Res. 21:155-160 (1981).
Polansky, J.R. et al.--In Vitro Correlates of Glucocorticoid Effects on Intraocular Presszure, Glaucoma Update IV, pp. 20-29 (1991).
Polansky, J.R. et al.--Eicosanoid Production and Glucocorticoid Regulatory Mechanisms in Cultured Human Trabecular meshwork Cells, The Ocular Effects of Prostaglandins and other Eicosanoids, pp. 113-138 (1989).
Polansky, J.R.--Side Effects of Topical Ophthalmic Therapy With Anti-Inflammatory Steroids and B-Blockers, Current Opinion in Ophthalmology 3;259-272 (1992).
Polansky, J.R. et al.--Growth Factor Effects and Modulation of Glucocorticoid (GC) and Other Stress Responses in Human Trabecular Meshwork (HTM) Cells, Experimental Eye Research 55:265 1992).
Polansky, J.R.--Basic Pharmacology of Corticosteroids, Current Topics in Ocular Inflammation, No. 1, pp. 9-21 (1993).
Polansky, J.R. et al.--HTM Cell Culture Model For Steroid Effects on Intraocular Pressure: Overview, Basic Aspects of Glaucoma Research III, pp. 307-318 (1993).
Polansky, et al.--Anti-inflammatory Agents: Steroids as Anti-Inflammatory Agents, Handbook of Experimental Pharmacology 69:491-503 (1984).
Polansky, et al.--Cellular Sensitivity to Glucocorticoids in Patients with POAG, Investigative Ophthalmology & Visual Science 26:805-809 (1985).
Ringvold, A. et al.--Electron Microscopy of the Trabecular Meshwork in Eyes with Exfoliation Syndrome, Virchows Arch. Abt. A Path. Anat. 353:110-127 (1971).
Rohen, J.W. et al.--The Phagocytic Activity of the Trabecular Meshwork Endothelium, Albrecht v. Graefes Arch. Clin. Exper. Ophthalmol. 175:143-160 (1968).
Shabo, A.L. et al.--Observations on the Fate of Blood in the Anterior Chamber, Amer. J. Ophthalmol. 73:25-36 (1972).
Sidman, K.R. et al.--Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid, Biopolymers 22:547-556 (1983).
Snyder, R.W. et al.--Cor
Bloom Ernest
Fauss Donald J.
Polansky Jon R.
Fay Zohreh
University of California
LandOfFree
Method for the treatment of a trabecular meshwork whose cells ar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of a trabecular meshwork whose cells ar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of a trabecular meshwork whose cells ar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2357678